Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Mixed Molecular Clinical Index (MMCI) in Diffuse Large B-cell Lymphoma (DLBCL) (MMCI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04300101
Recruitment Status : Not yet recruiting
First Posted : March 9, 2020
Last Update Posted : April 21, 2020
Sponsor:
Information provided by (Responsible Party):
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori

Brief Summary:

This is a prospective observational study. The primary objective is to identify new prognostic biomarkers for DLBCL patients in terms of progression-free survival (PFS) and able to add predictive capacity to recognized important clinical factors.

The secondary objectives are:

  • to identify new biomarkers associated with overall survival (OS) and objective response rate (ORR)
  • to characterize tissue and circulating immune microenvironment of DLBCL patients by bulk and single cell transcriptomics;
  • to assess the correlation between the expression of immune checkpoint genes and mRNA signature;
  • to describe the mutational status of a panel of genes relevant to DLBCL pathogenesis;.
  • to assess the correlation between protein expression, mutational status and the messenger RNA (mRNA) signature.

For each enrolled patient, immunohistochemical determinations will be performed: Cell of origin (COO) (Germinal Cell -GC- or activated B-cell - ABC- type according with Hans algorithm ), evaluation of cluster of differentiation antigen 20 (CD20), cluster of differentiation antigen 5 (CD5), cluster of differentiation antigen 10 (CD10), Bcl6, Bcl2 (cut off>50%), Multiple Myeloma 1 / Interferon Regulatory Factor 4 protein (MUM1/IRF4), c-myc (cut off>40%) and Ki67, fluorescence in situ hybridization (FISH) for c-myc and if rearranged, for Bcl2 e Bcl6 ). Moreover, paraffin embedded (FFPE) tumor specimens will be collected for RNA extraction and mRNA expression analysis and sent to Bioscience Laboratory of Istituto Scientifico Romagnolo per lo studio e la cura dei tumori (IRST-IRCCS).


Condition or disease Intervention/treatment
Diffuse Large B Cell Lymphoma Other: molecular characterization

Detailed Description:

Diffuse large B-cell lymphoma (DLBCL) is an heterogeneous group of cancers classified together on the basis of morphology, immunophenotype, genetic alterations and clinical behavior. The distinction of DLBCL into cell-of origin (COO) categories, based on patterns of gene expression reminiscent ( germinal center B-cell- the GC group and activated B-cell- the ABC group-), as defined and characterized by the Lymphoma & Leukemia Molecular Profiling Project (LLMPP), has profound biological, prognostic and potential therapeutic implications and in addiction, the negative prognostic effect of myelocytomatosis oncogene (MYC), B-cell lymphoma 2 (BCL2) and B-cell lymphoma-6 (BCL6) alterations in DLBCL has been showed largely dependent on COO subtypes . Furthermore, the combination of BCL2, MYC and BCL6 alterations with IPI (International Prognostic Index), identifies markedly worse prognostic groups within individual COO subtypes. The original methods used to define these entities, performed gene expression profiling (GEP) using microarrays on RNA derived from frozen tissue (FT). Subsequently, in an attempt to determine COO in standard practice using commonly available formalin-fixed paraffin-embedded tissue (FFPE) less precise but relatively inexpensive binary immunohistochemical (IHC) methods has been used . However in particular in non GC, the rate of concordance was unsatisfactory. A high degree of agreement has been demonstrated instead in COO determining, with a signature of 20 genes from formalin-fixed paraffin embedded (FFPE) tumor specimens, with Lymph2Cx kit (nCounter® Technology, NanoString Technologies), becoming the gold standard suggested in World Health Organization (WHO) classification . However recently, was demonstrated that the COO and BCL2, MYC, BCL6 status are not enough to describe the molecular risk of these patients, suggesting a genetic substructure that still to be discovered . Moreover, the tumor microenvironment and in particular the ratio of immune effectors and checkpoint molecules also have a prognostic role in DLBCL. Besides, elevated frequency of myofibroblasts, dendritic cells, and cluster of differentiation 4 (CD4) positive T cells correlated with better outcomes.

In conclusion, a comprehensive genomic analysis of these patients and a deep characterization of the immune compartment and immune checkpoints (Nanostring, immunohistochemistry for BCL2, MYC, BCL6, mutation analysis, proteomic analysis etc.) joined with IPI score, will allow the creation of a mixed, molecular, clinical, index (MMCI) to identify extremely poor prognostic groups, within each COO subtype, to consider a risk-adapted treatments in future.

It is a prospective observational study with a total duration of 36 months. The primary objective is the identification of new prognostic biomarkers for DLBCL patients in terms of progression-free survival (PFS) and able to add predictive capacity to recognized important clinical factors.

The secondary objectives are:

  • to identify new biomarkers associated with overall survival (OS) and objective response rate (ORR);
  • to characterize tissue and circulating immune microenvironment of DLBCL patients by bulk and single cell transcriptomics;
  • to assess the correlation between the expression of immune - checkpoint genes and mRNA signature;
  • to describe the mutational status of a panel of genes relevant to DLBCL pathogenesis;.
  • to assess the correlation between protein expression, mutational status and the mRNA signature.

For each enrolled patient, immunohistochemical determinations will be performed by each Pathology Unit: COO (GC o ABC type according with Hans algorithm ), evaluation of CD20, CD5, CD10, Bcl6, Bcl2 (cut off>50%), MUM1/IRF4, c-myc (cut off>40%) and Ki67, FISH for c-myc and if rearranged, for Bcl2 e Bcl6). Moreover, paraffin embedded (FFPE) tumor specimens will be collected for RNA extraction and mRNA expression analysis and centralised at IRST-IRCCS.

Layout table for study information
Study Type : Observational
Estimated Enrollment : 100 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Mixed Molecular Clinical Index (MMCI) in Diffuse Large B-cell Lymphoma (DLBCL)
Estimated Study Start Date : May 2020
Estimated Primary Completion Date : March 2023
Estimated Study Completion Date : March 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma

Group/Cohort Intervention/treatment
DLBCL patients
All patients with diagnosis of DLBCL
Other: molecular characterization

immunohistochemical determinations: Cell of Origin (COO) (according with Hans algorithm), evaluation of Cluster of Differentiation (CD) (CD20, CD5, CD10), Bcl6, Bcl2 (cut off>50%), MUM1/IRF4, c-myc (cut off>40%) and Ki67, FISH for c-myc and if rearranged for Bcl2 e Bcl6.

mRNA expression by Nanostring Single cell analysis Immune checkpoint expression Proteomic analysis Metabolic analysis





Primary Outcome Measures :
  1. identification of new prognostic biomarkers [ Time Frame: 3 years ]
    To identify new prognostic biomarkers for DLBCL patients that combined to clinical factors (IPI) are able to create a MMCI, predictive in terms of progression-free survival (PFS) of DLBCL patients.


Secondary Outcome Measures :
  1. identification of molecular and clinical parameters [ Time Frame: 3 years ]
    to identify molecular and clinical parameters associated with overall survival (OS) and objective response rate (ORR)

  2. characterization of tissue and circulating immune microenvironment [ Time Frame: 3 years ]
    to characterize tissue and circulating immune microenvironment by bulk and single cell transcriptomics

  3. immune checkpoint genes analysis [ Time Frame: 3 years ]
    to assess the correlation between the expression of immune checkpoint genes and mRNA signatures

  4. mutational status [ Time Frame: 3 years ]
    describe the mutational status of a panel of genes relevant to DLBCL pathogenesis

  5. Correlation of protein expression, mutational status and the mRNA signatures [ Time Frame: 3 years ]
    assess the correlation between protein expression, mutational status and the mRNA signatures.


Biospecimen Retention:   Samples With DNA
Formalin fixed Paraffin embedded (FFPE) tumor specimens and peripheral blood samples.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with a new diagnosis of High grade Diffuse large B cell Lymphoma
Criteria

Inclusion Criteria:

  • New diagnosis of High grade Diffuse large B cell Lymphoma
  • Signed written informed consent.

Exclusion Criteria:

  • Any other malignancy within 5 years (except for adequately treated carcinoma in situ of the cervix or basal or squamous cell skin cancer or surgically resected prostate cancer with normal PSA).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04300101


Contacts
Layout table for location contacts
Contact: Oriana Nanni, Dr +39 0543739100 oriana.nanni@irst.emr.it
Contact: Bernadette Vertogen, Dr +39 0544285813 cc.ubsc@irst.emr.it

Locations
Layout table for location information
Italy
Irst Irccs
Meldola, FC, Italy, 47014
Contact: Gerardo Musuraca, MD    +39 0543739100    gerardo.musuraca@irst.emr.it   
Ospedale S. Maria delle Croci RAVENNA
Ravenna, RA, Italy, 48121
Contact: Monica Tani, MD    054428    monica.tani@ausl.romagna.it   
Ospedale Infermi
Rimini, Italy, 47924
Contact: Annalia Molinari, MD       annalia.molinari@auslromagna.it   
Sponsors and Collaborators
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
Investigators
Layout table for investigator information
Principal Investigator: Gerardo Musuraca, MD IRST IRCCS
Layout table for additonal information
Responsible Party: Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori
ClinicalTrials.gov Identifier: NCT04300101    
Other Study ID Numbers: IRSTB094
First Posted: March 9, 2020    Key Record Dates
Last Update Posted: April 21, 2020
Last Verified: March 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori:
Diffuse Large B cell lymphoma;
cell of origin
gene expression
immunohistochemistry
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma
Lymphoma, B-Cell
Lymphoma, Large B-Cell, Diffuse
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin